Merck drug Janumet XR gains regulatory approval in Korea

Published: 2013-10-14 06:56:00

Updated: 2013-10-14 06:56:00

MSD Korea announced Thursday that the Ministry of Food and Drug Safety (MFDS) has recently approved Janumet XR (sitagliptin and metformin hydrochloride (HCl) extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of Janumet (sitagliptin), with extended-release metformin.

Janumet XR provides a convenient once-daily treatment op...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.